ABCL Stock — AbCellera Biologics Inc.: Cash, EV, Pipeline

What they do

AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates.

Source: 10-K FY2025 via SEC EDGAR

Share price

$12.55

Market cap

$4,063.7M

Cash

$764.4M

Enterprise value

$3,299.3M

Balance sheet

Cash	$764.4M
Debt	$0.0M
Net cash	$764.4M
Enterprise value	$3,299.3M
Basic shares	326.6M shares
Fully diluted shares	382.8M shares
Fully diluted market cap	$4,804.0M
Cash per share	$2.34
Quarterly burn	+$25.9M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

306.6M

Pre-funded warrants

0.0M

Options

66.3M

RSUs

9.8M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

382.8M

Cap table as of 2026-06-30.

Price history

Loading ABCL daily closes…

Loading price history…

Recently reported

ABCL575 Phase 1 Negative · 2026-11-09

atopic dermatitis

Primary: Safety/tolerability and pharmacokinetic endpoints of the Phase 1 single-ascending-dose study of ABCL575 (OX40L antibody) — endpoints as described in the release, no quantitative results disclosed — Phase 1 study met all endpoints, demonstrating a favorable tolerability profile and a pharmacokinetic profile that supports an extended dosing interval; AbCellera currently does not plan to develop ABCL575 past Phase 1

· No quantitative safety, PK or efficacy numbers disclosed in the release

Safety: Favorable tolerability profile per the release; no numbers disclosed

Figures auto-extracted, pending review.

Source release →

ABCL635 Phase 1/2 Positive · 2026-08-10

ABCL635 Phase 2 · moderate-to-severe vasomotor symptoms due to menopause

Source release →

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

ABCL635

Phase 2 · Active Modality: antibody

Target NK3R

Indications

moderate-to-severe vasomotor symptoms associated with menopause (Stage not disclosed)

Status note Phase 1/2 program in moderate-to-severe vasomotor symptoms. Target/modality from 10-K fallback.

ABCL575

Phase 1 · Active Modality: fully human half-life-extended monoclonal antibody

Target OX40L

Indications

not disclosed (Stage not disclosed)

Catalysts

— None

Status note Target/modality from 10-K fallback.

ABCL688

Preclinical · Active Modality: antibody

Indications

undisclosed autoimmune indication (Stage not disclosed)

Catalysts

— None

Status note IND/CTA-enabling antibody candidate. Target undisclosed in current 10-Q; 10-K describes target as undisclosed GPCR or ion channel/multipass membrane protein.

ABCL386

Preclinical · Active Modality: antibody

Indications

undisclosed oncology indication (Stage not disclosed)

Catalysts

— None

Status note IND/CTA-enabling antibody candidate against undisclosed oncology target. Jazz and Vertex collaborations cover unnamed discovery programs (no candidate rows created).

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ABCL635
Lead indication	Vasomotor Symptoms Associated With Menopause
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07118891	Phase 2	Active, not recruiting	Sponsor	ABCL	—	Vasomotor Symptoms Associated With Menopause; Healthy Volunteers	—
NCT07108894	Phase 1	Active, not recruiting	Sponsor	ABCL	—	Healthy Volunteers	Q4 2026 Est. Nov 15, 2026 · quarter midpoint

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for AbCellera Biologics Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	33,012,138	+2,736,200	1.30%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ABCL — AbCellera Biologics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ABCL — AbCellera Biologics Inc.